> ## Content Index
> Fetch the complete content index at: https://goodoil.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# Face of the Day
- URL: https://goodoil.news/face-of-the-day-824/
- Published: 2023-09-11T18:30:51.000Z
- Updated: 2023-09-10T20:12:10.000Z
- Author: Good Oil Staff
- Tags: General, Health, #wp, #wp-post, #Import 2024-07-16 22:22

> Doctors told Rotorua man Matthew Keogan to “let nature take its course” and then say goodbye to his family.  
>  
> Two days later on November 1, 2021, he was writing his will at his hospital bedside with lawyers.  
>  
> He had been given three to six months to live.  
>  
> “You sort of think of cancer as a death sentence. Once you’ve got cancer you’re gone,” Keogan said.  
>  
> But his oncologist suggested he try Pembrolizumab, known by the brand name Keytruda, a non-funded cancer immunotherapy medicine.  
>  
> The result has been miraculous.  
>  
> With the help of his medical insurance, Keogan, 51, has had 24 Keytruda infusions over the past two years costing more than $113,000\. Each early round of Keytruda costs $9745.10\. From the 10th round, each infusion cost $1700.  
>  
> Keogan’s most recent infusion was last week and on Tuesday doctors said his scans were mostly clear of cancer cells.  
>  
> He remains in remission and hopes his oncologist will today tell him that 2024 will be a treatment-free year.  
>  
> One year and 10 months later, Keogan feels he has “beaten the odds” with cancer.  
>  
> NZ Herald

[Read more here](https://www.nzherald.co.nz/nz/rotorua-man-with-stage-four-bowel-cancer-in-remission-after-taking-keytruda/5PIDNR4PGRD5PKB54F2ZJHAHDU/?ref=goodoil.news). Discuss it on *The BFD.*

[If you would like to access exclusive Member content or just remove the ads to make your reading experience more enjoyable click here to browse our Membership options.](https://thebfd.co.nz/subscription-plans/?ref=2)

[If you enjoyed this article please share it using the share buttons at the top or bottom of the article.](#)